By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.
The Voice of People With Breast Cancer
FIND THE BREAST CANCER DRUG INFORMATION YOU NEED
MedSearch
Generic Name
Trastuzumab deruxtecan
Brand Name
- Enhertu
- Astra Zeneca
- Stage IV (metastatic)
- HER2-ultra low
- Targeted therapy
- Injectable
- Listed on Provincial/Territorial drug Formulary
The process of getting a drug approved and publicly funded in Canada is complex and lengthy. CBCN has created an infographic on how drugs get funded in Canada to make understanding Canada’s drug approval process a little easier. Access the infographic here.
- Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, Québec, Saskatchewan
- No
- Yes
AstraZeneca Oncology Patient Support Program
Toll free: 1-877-280-6208
Fax: 1-877-280-6221
Email: enrollment@azoncologypsp.caHours of operation: Mon-Fri 8:00 AM - 8:00 PM ET
Patients with HR+ breast cancer should have received at least one and be no longer considered eligible for endocrine therapy. For eligible HR+/HER2-low metastatic breast cancer patients, the PSP will offer reimbursement navigation support; co-payment towards the cost of the drug (up to 20 percent) for those with private insurance and who are paying out of pocket; and a free drug program which offers financial support for Enhertu at full coverage for eligible patients who do not have private insurance and who have enrolled in the PSP between January 9, 2023 and January 31, 2024, or until public listing (whichever comes first). NOTE: HR-/HER2-low patients will be eligible for reimbursement navigation support, educational resources and co-payment towards the cost of the drug (up to 20 percent) for those with private insurance or who are paying out of pocket but will NOT be eligible for free drug at this time.
Receive updates by email Subscribe Now
About CBCN
CBCN strives to voice the views and concerns of breast cancer patients through education, advocacy activities, and the promotion of information sharing.
Canadian Breast Cancer Network
185 Somerset St. West Suite 318, Ottawa, ON Canada K2P 0J2
Tel: 613-230-3044
Toll-free: 1-800-685-8820
Email Us
